SCHEMBL2222210

SCHEMBL2222210

CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cc1OC1CCOC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 20/20 1.00
ERBB2 P04626 7/20 0.80
ERBB4 Q15303 3/20 0.80
GAK O14976 2/20 0.80
ABL1 P00519 2/20 0.80
LCK P06239 2/20 0.80
MET P08581 2/20 0.80
PHKG2 P15735 2/20 0.80
BLK P51451 2/20 0.80
IRAK1 P51617 2/20 0.80
DYRK1A Q13627 2/20 0.80
HIPK4 Q8NE63 2/20 0.80
EPHA6 Q9UF33 2/20 0.80
CIT O14578 1/20 0.80
EPHB6 O15197 1/20 0.80
RIPK2 O43353 1/20 0.80
STK10 O94804 1/20 0.80
LYN P07948 1/20 0.80
RET P07949 1/20 0.80
CHRM2 P08172 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Afatinib SCHEMBL29388685 0.89 EGFR (1.00) EGFRERBB2ERBB4GAKABL1
Afatinib SCHEMBL2865630 0.89 EGFR (1.00) EGFRERBB2ERBB4GAKABL1
Afatinib SCHEMBL2269415 0.89 EGFR (1.00) EGFRERBB2ERBB4GAKABL1
Afatinib SCHEMBL232772 0.89 EGFR (1.00) EGFRERBB2ERBB4GAKABL1
Afatinib SCHEMBL185621 0.89 EGFR (1.00) EGFRERBB2ERBB4GAKABL1
Afatinib SCHEMBL185786 0.89 EGFR (1.00) EGFRERBB2ERBB4GAKABL1
Afatinib SCHEMBL2865634 0.89 EGFR (1.00) EGFRERBB2ERBB4GAKABL1
Afatinib SCHEMBL231073 0.89 EGFR (1.00) EGFRERBB2ERBB4GAKABL1
Afatinib SCHEMBL231072 0.89 EGFR (1.00) EGFRERBB2ERBB4GAKABL1
Afatinib SCHEMBL28409673 0.89 EGFR (1.00) EGFRERBB2ERBB4GAKABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011084796-A2 NOVEL QUINAZOLINE DERIVATIVES ZHANG QIANG 2011-07-14 WO claimed
US-8735409-B2 Quinazoline derivatives ZHANG QIANG (US) 2014-05-27 US disclosed
US-20130035350-A1 Novel Quinazoline Derivatives ZHANG QIANG (US) 2013-02-07 US disclosed
WO-2011084796-A2 NOVEL QUINAZOLINE DERIVATIVES ZHANG QIANG 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130035350-A1 Novel Quinazoline Derivatives ERBB2, ERBB3, EGFR EGFR 3/4885ERBB2 1/4885ERBB4 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.